
An MHC tetramer is a reagent that makes a single antigen-specific T cell visible. It is built from four copies of an MHC molecule, each loaded with the peptide of interest, joined through a fluorescently labeled streptavidin core. Because the complex carries four binding sites instead of one, it grips a T-cell receptor far more firmly than a lone MHC-peptide complex does, and a labeled population of these cells can then be counted directly by flow cytometry. A custom MHC tetramer service produces this reagent to a customer's exact peptide and allele, so the result matches the antigen under study rather than a stock catalog entry.
The method has been a standard tool in cellular immunology since the 1990s, and it remains the most direct way to qualify and quantify antigen-specific T cells in blood or tissue for research.
A T-cell receptor recognizes a peptide sitting in the groove of an MHC molecule, but that interaction on its own is weak and short-lived, so a single complex slips off the receptor before the cell can be scored. Linking four identical MHC-peptide complexes into one tetramer changes that: the multivalent reagent can engage three or four receptors on the same T cell at once, which lifts the binding strength and specificity enough for reliable detection. The fluorescent label on the streptavidin core then makes the bound cells bright in a flow-cytometry gate.
The assembly follows a defined sequence, and each step is checked before the next begins.
The service is offered across the major human and animal systems so that the reagent can be matched to the model in use.
MHC tetramers are used wherever the question is which T cells, and how many, recognize a defined peptide. Typical uses include epitope mapping and peptide-affinity ranking, immune monitoring of infection or vaccination, the study of autoimmune and tumor-associated responses, and the characterization of engineered or therapeutic T cells. Because the readout is single-cell and quantitative, the reagent fits both discovery screens and longitudinal studies.
A project begins when the customer supplies the peptide sequence and the target allele, which are assessed for a workable pairing. If the combination is expected to fold and load, the tetramer is synthesized under a defined agreement; if the pairing is unlikely to succeed, that assessment is reported before any synthesis is committed. The finished material is delivered with a quality report covering folding, loading, and labeling, and the format is chosen to suit the assay — by number of tests or by mass, with larger batches available on request.